Human papillomavirus (HPV) vaccines applied in national vaccination programs protect against most cancers associated with oncogenic, high-risk (hr) HPV types. Two recent studies demonstrate the impact of gender-neutral HPV vaccination in the overall protection against hrHPV infections already with low vaccination coverage.